The Pharma Data

JANUARY 5, 2021

Ribometrix’s technology platform focuses on identify 3D “motifs” in RNA molecules so it can then design small molecule drugs that bind to these motifs to treat diseases. Targeting RNA is believed to be a way to develop therapeutics for so-called undruggable proteins. This is not the first deal for RNA therapeutics for Genentech.

RNA 52

RNA Protein Bioavailability DNA 52

The Pharma Data

NOVEMBER 22, 2020

Alzprotect co-owns or has an exclusive worldwide license from the French National Institute of Health and Medical research (Inserm) and the University of Lille (France) on a total of 58 patents related to Ezeprogind in 39 countries. EZEPROGIND, which is kicking off phase 2a trials, is a bioavailable neurotrophic inducer.

Drugs 40

Drugs Protein Bioavailability Development 40

Delveinsight

FEBRUARY 16, 2021

Chemotherapy drugs while killing cancer cells also damages normal tissues. The drug is the first and only therapy that is developed and approved to protect bone marrow (myeloprotection), which is injected prior to treatment with chemotherapy, asserts the US oncology drug developer, G1.

Marketing 52

Marketing Protein Bioavailability Drugs 52

Delveinsight

JANUARY 7, 2021

Ikena secures USD 120 Million to advance a growing pipeline of cancer drugs. Ikena Oncology has bagged USD 120 million to develop its expanding pipeline of cancer drugs. The newer side of the pipeline points targeted oncology drugs. Terns raises USD 87 Million for NASH drugs. IND-enabling studies are underway.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

The Pharma Data

DECEMBER 9, 2020

Atlas cofounded, seeded and incubated Vigil, with pre-clinical stage assets in-licensed from Amgen Inc., The company plans to do this by developing drugs that eliminate protein aggregation by either reducing the production of toxic proteins or removing them after the fact through autophagy. SciNeuro Pharmaceuticals.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

The Pharma Data

AUGUST 16, 2021

Lebrikizumab is a novel monoclonal antibody (mAb) that binds soluble IL-13 with high affinity, has high bioavailability, a long half-life and blocks IL-13 signaling. “Lebrikizumab is a specific inhibitor of IL-13 that offers robust binding affinity and high bioavailability. 1-4 The U.S. ’s Chief Scientific Officer.

Dermatology 40

Dermatology Trials Bioavailability Medicine 40

The Pharma Data

NOVEMBER 11, 2020

Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for SLV213 for the treatment of COVID-19 and has dosed the first subjects in a Phase 1 clinical study. While SLV213 can be dosed orally or intravenously, Selva is first advancing it as an oral drug candidate for COVID-19. About SLV213.

Protein 52

Protein Bioavailability Development Licensing 52